Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
EMvision Medical Devices Ltd. Business Overview & Revenue Model
EMvision Medical Devices Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.05M | 5.05M | 11.22M | 6.97M | 4.36M | 1.70M |
| Gross Profit | 5.05M | 5.05M | 11.22M | 6.63M | 4.12M | 1.58M |
| EBITDA | -8.71M | -8.71M | -8.35M | -5.99M | -7.84M | -9.56M |
| Net Income | -9.81M | -9.81M | -2.73M | -3.87M | -6.11M | -8.40M |
Balance Sheet | ||||||
| Total Assets | 15.57M | 15.57M | 23.97M | 11.52M | 8.51M | 10.77M |
| Cash, Cash Equivalents and Short-Term Investments | 10.53M | 10.53M | 18.67M | 9.97M | 6.80M | 9.69M |
| Total Debt | 3.53M | 3.53M | 2.90M | 3.04M | 737.86K | 213.17K |
| Total Liabilities | 6.29M | 6.29M | 5.46M | 6.40M | 1.43M | 720.01K |
| Stockholders Equity | 9.28M | 9.28M | 18.52M | 5.12M | 7.08M | 10.05M |
Cash Flow | ||||||
| Free Cash Flow | -7.89M | -7.89M | -6.29M | 646.86K | -3.97M | -4.62M |
| Operating Cash Flow | -7.84M | -7.84M | -5.99M | 834.15K | -3.78M | -4.49M |
| Investing Cash Flow | -50.37K | -50.37K | -302.41K | -187.29K | -191.12K | -127.25K |
| Financing Cash Flow | -258.34K | -258.34K | 15.00M | 2.52M | 1.08M | 8.90M |
EMvision Medical Devices Ltd. Technical Analysis
EMvision Medical Devices Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$274.30M | -78.71 | -4.06% | ― | 20.36% | 64.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$61.51M | -46.38 | -6.35% | ― | 2.23% | -263.16% | |
48 Neutral | $73.35M | ― | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$176.12M | -16.52 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% |
EMvision Medical Devices Ltd. Corporate Events
EMVision Medical Devices Ltd has made significant progress in its Pivotal (Validation) Trial for the emu™ brain scanner, aimed at supporting regulatory submission and market entry in the US and other global markets. The company has expanded its clinical footprint in the US with the activation of UCLA Health as a trial site, and recruitment is expected to accelerate. EMVision also received a $3 million grant to evaluate an expedited stroke care model in regional hospitals, highlighting the alignment of its mission with government priorities for equitable healthcare access. Additionally, the company raised $12 million through a placement, bolstering its financial position with cash reserves of $18.35 million as of September 2025.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Limited announced that its Share Purchase Plan (SPP) has been oversubscribed, prompting the company to close the plan earlier than initially scheduled. The early closure indicates strong investor interest and support, potentially enhancing the company’s financial position and ability to advance its product development efforts.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has successfully executed a Cooperative Research Centres Projects (CRC-P) Grant Agreement with the Australian Government, receiving an initial payment of $453,566. This grant will support a collaborative project aimed at improving stroke diagnosis and management in regional emergency departments across Australia, utilizing EMVision’s emu™ point-of-care brain scanner. The study aims to demonstrate the clinical benefits of this technology, potentially leading to widespread adoption and improved patient outcomes in underserved rural areas.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has announced the details of its upcoming Annual General Meeting, scheduled for November 11, 2025, at their Macquarie Park office. The company is encouraging shareholders to participate by voting through proxy forms, which can be submitted via various methods, including online and mail. This meeting is crucial for stakeholders as it provides an opportunity to engage with the company’s strategic direction and governance.
The most recent analyst rating on (AU:EMV) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has announced a Share Purchase Plan (SPP) for its shareholders, allowing them to subscribe for fully paid ordinary shares at a price of A$1.94 per share, with a maximum subscription of A$30,000. Additionally, shareholders who participate in the SPP will be eligible for free-attaching quoted options, exercisable at $3.40 each, expiring two years from the issue date. This initiative is part of the company’s efforts to raise capital and engage its shareholders, potentially impacting its financial stability and market positioning positively.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$3.15 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd. has announced a Share Purchase Plan (SPP) offering eligible shareholders the opportunity to purchase new shares at a discounted price of A$1.94 per share, which is a 16.4% discount from the last closing price. This initiative aims to raise capital while providing shareholders with additional investment opportunities through free-attaching quoted options. The offer underscores the company’s strategy to enhance its financial position, potentially impacting its market presence and shareholder value.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has announced the issuance of 6,185,567 fully paid ordinary shares at $1.94 per share, alongside 205,574 shares following the exercise of unlisted Performance Rights. Additionally, the company is launching a Share Purchase Plan (SPP) to raise up to $1 million, with the potential to accept oversubscriptions up to $2 million. This move is intended to strengthen the company’s financial position and support its ongoing operations and growth initiatives.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has commenced a Pre-Hospital Mobile Stroke Unit (MSU) Study in Melbourne to evaluate their First Responder Brain Scanner. This study, conducted in collaboration with the Australian Stroke Alliance, Ambulance Victoria, and the Royal Melbourne Hospital, aims to assess the usability and workflow integration of the device in a real-world MSU setting. The study is significant as it seeks to address the need for scalable pre-hospital stroke care solutions, potentially impacting the company’s market positioning by advancing the development and validation of their device through the FDA 510(k) regulatory pathway.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd. has announced a change in its substantial holder status, as Scott Kirkland ceased to be a substantial holder on September 24, 2025. This change occurred due to a dilution resulting from the issuance of additional shares, affecting 4,276,987 ordinary shares. The announcement reflects a shift in the company’s shareholder structure, which may influence the company’s governance and strategic decisions.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the quotation of 205,574 fully paid ordinary securities on the ASX, effective September 24, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the issuance of new unquoted equity securities, specifically performance rights set to expire on June 30, 2030. This move is part of an employee incentive scheme and reflects the company’s strategy to motivate and retain talent, potentially impacting its operational capabilities and market position positively.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the quotation of 6,185,567 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 24, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially strengthening its market position and benefiting stakeholders by supporting ongoing and future projects.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd announced a correction to a previous statement regarding the proposed issue of securities under a securities purchase plan. The update includes specifying countries that will not be eligible for the securities offer, which could impact the company’s market reach and investor engagement.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has successfully secured $12.0 million through a placement of shares, with strong backing from institutional and sophisticated investors, including strategic shareholder Keysight Technologies. The funds will be used to advance the company’s emuTM and First Responder programs through significant milestones, including FDA submission and initial commercialization activities, over the fiscal years 2026 and 2027. Additionally, a Share Purchase Plan (SPP) is being launched to allow eligible shareholders to purchase shares on similar terms, further supporting the company’s clinical, regulatory, and market access initiatives.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has announced that its Annual General Meeting (AGM) will be held on November 11, 2025, in Sydney. The meeting will include discussions on various resolutions, and nominations for director positions must be submitted by September 22, 2025. This announcement is part of the company’s ongoing efforts to engage with shareholders and stakeholders, reflecting its commitment to transparency and governance.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has requested a trading halt on its securities pending an announcement regarding a capital raising. This move indicates a potential strategic financial maneuver aimed at bolstering the company’s resources, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Limited has announced its participation in the E&P Small Cap Healthcare Conference and the company’s Go-To-Market Strategy Webinar. The presentation, led by CEO and Co-Founder Scott Kirkland, aims to inform shareholders and the market about the company’s strategic plans. This announcement highlights EMVision’s efforts to strengthen its market presence and engage with stakeholders, potentially impacting its operations and industry positioning.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Limited announced a Go-To-Market Strategy Webinar scheduled for September 9, 2025, where CEO Scott Kirkland will present. This webinar is a strategic move for EMVision as it seeks to enhance its market presence and engage stakeholders, potentially impacting its operations and positioning within the medical device industry.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has released its corporate governance statement, which is now available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating their commitment to transparency and accountability. This move is likely to enhance stakeholder confidence and reinforce the company’s industry positioning as a responsible and well-governed entity.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd. announced significant progress in FY25, particularly with its EMView brain scanner, which showed high accuracy in identifying stroke types in a multi-site study. This success has increased global visibility and facilitated the commencement of a pivotal trial for FDA clearance. The trial involves collaboration with leading medical institutions, enhancing the company’s position in the stroke care industry. Additionally, the company has advanced its ultra-light First Responder brain scanner, completing initial aeromedical testing, which demonstrates its potential for use in remote and regional areas.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd announced the activation of UCLA Health as the final site for their Pivotal Trial, which is crucial for their De Novo submission to the FDA. The trial aims to assess the diagnostic performance of their emu™ brain scanner in detecting acute strokes. The company is on track to meet its recruitment targets by the first half of 2026. Additionally, a Trial Steering Committee comprising international stroke experts has been established to provide strategic guidance, enhancing the trial’s credibility and potential for regulatory approval.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMVision Medical Devices Ltd has been awarded a $3 million non-dilutive grant from the Australian Government to conduct a study on improving stroke care in regional Australia using their emu™ point-of-care brain scanners. This study, supported by partners such as Titan Pre-hospital Innovation and the Australian Stroke Alliance, aims to demonstrate the clinical benefits of the emu™ device, which could accelerate its adoption and commercialization. The project seeks to address stroke care inequalities in rural areas by enhancing diagnostic capabilities and refining care workflows, potentially leading to better patient outcomes and positioning EMVision as a leader in regional stroke care solutions.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.
EMvision Medical Devices Ltd has announced the issuance of new unquoted securities, including 800,000 options expiring in February 2029 and 200,000 performance rights expiring in August 2030. These securities are part of an employee incentive scheme and are not intended to be quoted on the ASX, reflecting the company’s strategy to motivate and retain talent, potentially enhancing its operational capabilities and market position.
The most recent analyst rating on (AU:EMV) stock is a Buy with a A$2.95 price target. To see the full list of analyst forecasts on EMvision Medical Devices Ltd. stock, see the AU:EMV Stock Forecast page.